These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 18565875)

  • 1. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle.
    Schimmel J; Larsen KM; Matic I; van Hagen M; Cox J; Mann M; Andersen JS; Vertegaal AC
    Mol Cell Proteomics; 2008 Nov; 7(11):2107-22. PubMed ID: 18565875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
    Bailey D; O'Hare P
    Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis.
    Castorálová M; Březinová D; Svéda M; Lipov J; Ruml T; Knejzlík Z
    Biochim Biophys Acta; 2012 Apr; 1823(4):911-9. PubMed ID: 22306003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin-like modifier FAT10 interferes with SUMO activation.
    Aichem A; Sailer C; Ryu S; Catone N; Stankovic-Valentin N; Schmidtke G; Melchior F; Stengel F; Groettrup M
    Nat Commun; 2019 Oct; 10(1):4452. PubMed ID: 31575873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
    González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
    Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition.
    Matafora V; D'Amato A; Mori S; Blasi F; Bachi A
    Mol Cell Proteomics; 2009 Oct; 8(10):2243-55. PubMed ID: 19596686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Characterization of SUMO-SIM Interactions.
    Husnjak K; Keiten-Schmitz J; Müller S
    Methods Mol Biol; 2016; 1475():79-98. PubMed ID: 27631799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converging Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Signaling: Improved Methodology Identifies Co-modified Target Proteins.
    Cuijpers SAG; Willemstein E; Vertegaal ACO
    Mol Cell Proteomics; 2017 Dec; 16(12):2281-2295. PubMed ID: 28951443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-dependent proteolytic control of SUMO conjugates.
    Uzunova K; Göttsche K; Miteva M; Weisshaar SR; Glanemann C; Schnellhardt M; Niessen M; Scheel H; Hofmann K; Johnson ES; Praefcke GJ; Dohmen RJ
    J Biol Chem; 2007 Nov; 282(47):34167-75. PubMed ID: 17728242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
    Eisenhardt N; Chaugule VK; Pichler A
    Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.
    van Hagen M; Overmeer RM; Abolvardi SS; Vertegaal AC
    Nucleic Acids Res; 2010 Apr; 38(6):1922-31. PubMed ID: 20026589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
    Citro S; Chiocca S
    Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
    Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
    Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
    Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
    J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the tumor suppressor PTEN by SUMO.
    González-Santamaría J; Campagna M; Ortega-Molina A; Marcos-Villar L; de la Cruz-Herrera CF; González D; Gallego P; Lopitz-Otsoa F; Esteban M; Rodríguez MS; Serrano M; Rivas C
    Cell Death Dis; 2012 Sep; 3(9):e393. PubMed ID: 23013792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of SUMO-dependent ubiquitylation in vitro.
    Keusekotten K; Praefcke GJ
    Methods Mol Biol; 2012; 832():111-23. PubMed ID: 22350879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMO chains: polymeric signals.
    Vertegaal AC
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):46-9. PubMed ID: 20074033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puromycin induces SUMO and ubiquitin redistribution upon proteasome inhibition.
    Matsumoto H; Saitoh H
    Biochem Biophys Res Commun; 2016 Jul; 476(3):153-8. PubMed ID: 27181354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain.
    Sriramachandran AM; Meyer-Teschendorf K; Pabst S; Ulrich HD; Gehring NH; Hofmann K; Praefcke GJK; Dohmen RJ
    Nat Commun; 2019 Aug; 10(1):3678. PubMed ID: 31417085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins.
    Su HL; Li SS
    Gene; 2002 Aug; 296(1-2):65-73. PubMed ID: 12383504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.